BC Innovations | Apr 4, 2019
Translation in Brief

Promoting AAV vectors to safety

Companies looking to make AAVs safer for gene therapies may need to test the vectors' genomic cargo for toxicity, according to a new study from a Harvard and Hong Kong group. Adeno-associated viral (AAV) vectors...
BC Extra | Jan 17, 2019
Preclinical News

NIH to bring iPS cell therapy into clinic for dry macular degeneration

Researchers at NIH's National Eye Institute (NEI) developed clinical-grade protocols for producing an autologous induced pluripotent stem cell-derived therapy for dry age-related macular degeneration. NEI plans to use the methods, reported in a Science Translational...
BC Extra | Mar 19, 2018
Clinical News

Stem cell-derived implant improves AMD patients' vision

U.K. researchers reported in Nature Biotechnology that a human embryonic stem cell (hESC)-derived retinal pigment epithelial (RPE) “patch” improved visual acuity in two patients with severe wet age-related macular degeneration in a suspended Phase I...
BC Extra | Mar 7, 2018
Preclinical News

Nanowire artificial photoreceptor array implant could restore vision

In a paper published in Nature Communications , researchers at Fudan University developed an array of nanowire artificial photoreceptors and suggested that subretinal implantation of the array could restore vision in patients with retinitis pigmentosa or...
BC Innovations | Jan 4, 2018
Distillery Therapeutics

Ophthalmic disease

INDICATION: Retinitis Rat studies suggest transplants of human embryonic stem cell (hESC)-derived retinal pigment epithelial (RPE) sheets could help treat retinitis pigmentosa. The sheets were generated by culturing hESC-derived RPEs on a human amniotic membrane...
BC Extra | Dec 21, 2017
Preclinical News

Researchers develop hESC-derived RPE cell sheet

In a paper published in Science Translational Medicine , researchers from Institut National de la Santé et de la Recherche Médicale (INSERM) and colleagues developed a technique to grow human stem cell-derived retinal pigment epithelial (RPE)...
BC Week In Review | Dec 1, 2017
Clinical News

BioTime reports Phase I/IIa data for dry AMD candidate

BioTime Inc. (NYSE-M:BTX; Tel Aviv:BTX) reported data from 6 evaluable patients with dry age-related macular degeneration (AMD) in a Phase I/IIa trial showing that subretinal transplantation of 50,000 or 200,000 OpRegen cells was well tolerated...
BC Week In Review | Mar 18, 2017
Company News

RIKEN researchers report feasibility of iPSC-based autologous transplantation in AMD

Researchers at the RIKEN Center for Developmental Biology (Kobe, Japan) and colleagues reported data from a case study in an issue of the New England Journal of Medicine showing the feasibility of transplanting a sheet...
BC Week In Review | Nov 16, 2015
Company News

Ocata Therapeutics, Astellas deal

Astellas will acquire cell therapy company Ocata for $8.50 per share, or $379 million in cash. The price represents a 91% premium to Ocata’s close of $4.46 on Nov. 9, before the deal was announced....
BC Extra | Nov 11, 2015
Top Story

Astellas buying Ocata for $379M

Astellas Pharma Inc. (Tokyo:4503) announced late Monday night that it will acquire cell therapy company Ocata Therapeutics Inc. (NASDAQ:OCAT) for $8.50 per share, or $379 million in cash. The price represents a 91% premium to...
Items per page:
1 - 10 of 98